Download PDF
Aktuelle Rheumatologie 2012; 37(04): 238-242
DOI: 10.1055/s-0032-1304304
Übersichtsarbeit
© Georg Thieme Verlag KG Stuttgart · New York

Ist der Einsatz von Parathormon bei sekundärer Osteoporose im Rahmen von entzündlich-rheumatischen Erkrankungen sinnvoll?

Is the Administration of Parathyroid Hormone in Inflammatory Rheumatic Diseases with Secondary Osteoporosis a Reasonable Therapeutic Option?
U. Lange
1   Kerckhoff-Klinik, Universität Gießen, Rheumatologie, Klinische Immunologie, Physikalische Medizin und Osteologie, Bad Nauheim
› Author Affiliations
Further Information

Publication History

Publication Date:
09 March 2012 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Entzündlich-rheumatische Erkrankungen gehen oft mit einer sekundären Osteoporose einher. Die Ätiologie des Knochenmasseverlustes ist multifaktoriell, wobei der Entzündungsaktivität eine zentrale Rolle zukommt. Die häufig eingesetzten Glukokortikoide nehmen zudem über verschiedene Mechanismen Einfluss auf den Knochenstoffwechsel und die Knochenmasse. Ob der Einsatz von Parathormon bei sekundärer Osteoporose im Rahmen von entzündlich-rheumatischen Erkrankungen sinnvoll ist, wird in dem vorliegenden Artikel abgehandelt.

Abstract

Inflammatory rheumatic diseases are often accompanied with secondary osteoporosis. The aetiology of bone loss is due to many factors, a central role is played by the inflammatory activity. Glucocorticoids that are often applied in the therapy regime influence bone metabolism and bone mass in different ways. Whether or not the administration of the osteoanabolic parathormone is a reasonable therapeutic option in inflammatory rheumatic diseases with secondary osteoporosis is discussed in the present overview.

Schlüsselwörter

entzündlich-rheumatische Erkrankungen - Osteoporose - Parathormon

Key words

inflammatory rheumatic diseases - secondary osteoporosis - parathyroid hormone
 

  • Literatur

  • 1 Lange U, Müller-Ladner U, Pfeilschifter J. Osteoporose. Leitliniengerechte Prophylaxe. Diagnostik und Therapie. Internist 2011; 52: 843-854
    PubMedGoogle Scholar
  • 2 Lehmann G, Wolf G. Teriparatid – ein Überblick. Arzneimitteltherapie 2010; 28: 277-282
    PubMedGoogle Scholar
  • 3 Brown EM. Physiology and pathopyhsiology of the extracellular calcium-sensing-receptor. Am J Med 1999; 106: 238-253
    CrossrefPubMedGoogle Scholar
  • 4 Kronenberg HM. PTH: mechanism of action, in primer on metabolic bone diseases. In: Favus M. (ed.) American Society of Bone and Mineral Research. 3rd edition Lippincott Raven; 1996: 68-70
    Google Scholar
  • 5 Morley P, Whitfield JF, Willick GE. Parathyroid hormone: an anaboloic treatment for osteoporosis. Curr Pharm Des 2001; 7: 671-687
    CrossrefPubMedGoogle Scholar
  • 6 Ma YL, Cain RL, Halladay DL et al. Catabolic effects of continous human PTH (1-38) in vivo is associated with substained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 2001; 142: 4047-4054
    CrossrefPubMedGoogle Scholar
  • 7 Fu Q, Jilka RL, Manolagas SC et al. Parathyroid hormone stimulates receptor activator of NF kappa b ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J Biol Chem 2002; 277: 48868-48875
    CrossrefPubMedGoogle Scholar
  • 8 Lee SK, Lorenzo JA. Regulation of receptor activator of nuclear factor-kappa B ligand and osteoprotegerin mRNA expression by parathyroid hormone is predominantly mediated by the protein kinase a pathway in murine bone marrow cultures. Bone 2002; 31: 252-259
    CrossrefPubMedGoogle Scholar
  • 9 Bauer W, Aub JC, Albright F. Studies of calcium and phosphorus metabolism. V. A study of the bone trabecular as a readily available reserve of calcium. J Exp Med 1929; 49: 145-161
    CrossrefPubMedGoogle Scholar
  • 10 Niall HD, Sauer RT, Jacobs JW et al. The amino-acid sequence of the amino-terminal 37 residues of human parathyroid hormone. Proc Natl Acad Sci USA 1974; 71: 384-388
    CrossrefPubMedGoogle Scholar
  • 11 Reeve J, Meunier PJ, Parsons JA et al. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J 1980; 280: 1340-1344
    CrossrefPubMedGoogle Scholar
  • 12 Dempster DW, Cosman F, Kurland ES et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001; 16: 1846-1853
    CrossrefPubMedGoogle Scholar
  • 13 Jiang Y, Zhao JJ, Mitlak BH et al. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003; 18: 1932-1941
    CrossrefPubMedGoogle Scholar
  • 14 Compston JE. Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure. Bone 2007; 40: 1447-1452
    CrossrefPubMedGoogle Scholar
  • 15 Lange U, Neumann E. Knochen und Entzündung – molekulare Mechanismen, neue pathophysiologische Stoffwechselwege und innovative Therapieansätze. Osteologie 2009; 1: 41-44
    PubMedGoogle Scholar
  • 16 Lange U. Osteoporose und Rheuma – molekulare Mechanismen. Orthopädische Praxis 2011; 47 (07) 352-356
    PubMedGoogle Scholar
  • 17 Teitelbaum SL. Bone resorption by osteoclasts. Science 2000; 289: 1504-1508
    CrossrefPubMedGoogle Scholar
  • 18 Dobnig H, Turner RT. The effects of programmes administration of human parathyroid hormone fragment 1-34 on bone histomorphometry and serum chemistry in rats. Endocrinology 1997; 138: 4607-4612
    CrossrefPubMedGoogle Scholar
  • 19 Jilka RL, Weinstein RS, Bellido T et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999; 104: 439-446
    CrossrefPubMedGoogle Scholar
  • 20 Dobnig H, Turner RT. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 1995; 136: 3632-3638
    CrossrefPubMedGoogle Scholar
  • 21 Rodan GA, Martin TJ. Role of osteoblasts in hormonal control of bone resorption – a hypothesis. Calcif Tissue Int 1981; 33: 349-351
    CrossrefPubMedGoogle Scholar
  • 22 Lange U, Teichmann J, Strunk J et al. Association of 1.25 vitamin D3 deficiency, disease activity and low bone mass in ankylosing spondylitis. Osteoporos Int 2005; 16: 1999-2004
    CrossrefPubMedGoogle Scholar
  • 23 Oelzner P, Müller A, Deschner F et al. Relationship between disease activity and serum levels of vitamin D metabolites and PTH in rheumatoid arthritis. Calcif Tissue Int 1998; 62: 193-198
    CrossrefPubMedGoogle Scholar
  • 24 Oelzner P, Buttgereit F, Demary W et al. Mechanismen des Knochenmasseverlustes bei rheumatoider Arthritis. Darstellung anhand einer Kasuistik. Z Rheumatol 2007; 66: 337-340
    PubMedGoogle Scholar
  • 25 Schett G, Kiechl S, Weger S et al. High-sensitive C-reactive protein and risk of nontraumatic fractures in the Bruneck study. Arch Intern Med 2006; 166: 2495-2501
    CrossrefPubMedGoogle Scholar
  • 26 Hofbauer L, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004; 292: 490-495
    CrossrefPubMedGoogle Scholar
  • 27 Neumann E, Gay S, Müller-Ladner U. The RANK/RANKL/osteoprotegerin system in rheumatoid arthritis: new insights from animal models. Arthritis Rheum 2005; 52: 2960-2967
    CrossrefPubMedGoogle Scholar
  • 28 Allali F, Breban M, Porcher R et al. Increase in bone mineral density of patients with spondylarthropathy treated with anti-tumour necrosis factor α. Ann Rheum Dis 2003; 62: 347-349
    CrossrefPubMedGoogle Scholar
  • 29 Lange U, Teichmann J, Müller-Ladner U et al. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-α antibody: a prospective open-label pilot study. Rheumatol. 2005 44. 1546-1548
    PubMedGoogle Scholar
  • 30 Vis M, Havaardsholm EA, Haugeberg G et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and RANKL serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 1495-1499
    CrossrefPubMedGoogle Scholar
  • 31 Neumann E, Schett G. Knochenstoffwechsel. Z Rheumatol 2007; 66: 286-289
    CrossrefPubMedGoogle Scholar
  • 32 Sato K, Suematsu A, Okamoto K et al. Th 17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006; 2673-2682
    PubMedGoogle Scholar
  • 33 Lubberts E, Koenders MI, Oppers-Walgreen B et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2005; 50: 650-659
    PubMedGoogle Scholar
  • 34 Liu XH, Kirschenbaum A, Yao S et al. Interactive effect of interleukin-6 and prostaglandine E2 on osteoclastogenesis via OPG/RANKL/RANK system. Ann N Y Acad Sci 2006; 1068: 225-233
    CrossrefPubMedGoogle Scholar
  • 35 Wong PK, Quinn JM, Sims NA et al. Interleukin-6 modulates production of T lyphocytes-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum 2006; 54: 158-168
    CrossrefPubMedGoogle Scholar
  • 36 Lange U. Aktualisierte DVO-Leitlinie Osteoporose 2009 – Glukokortikoide und andere Risikofaktoren. Orthopädie & Rheuma 2010; 5: 37-40
    PubMedGoogle Scholar
  • 37 Saag KG, Shane E, Boonen S et al. Teriparatide or alendronate in Glukokorticoid-induced osteoporosis. N Engl J Med 2007; 357 (20) 2028-2039
    CrossrefPubMedGoogle Scholar
  • 38 Langdahl BL, Marin F, Shane E et al. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int 2009; 20 (12) 2095-2104
    CrossrefPubMedGoogle Scholar
  • 39 Dobnig H, Warner MR, Langdahl BL et al. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis. Effects of gender and postmenopausal status – 24month results. Bone 2009; 44: S212
    PubMedGoogle Scholar